European Journal of Heart Failure最新文献_第5页

Visit-to-visit changes in heart rate in heart failure: A pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials 心力衰竭患者心率的逐次变化：PARADIGM-HF 和 PARAGON-HF 试验的参与者层面汇总分析

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-22 DOI: 10.1002/ejhf.3487

Henri Lu, Brian L. Claggett, Milton Packer, Marc A. Pfeffer, Karl Swedberg, Jean Rouleau, Michael R. Zile, Martin Lefkowitz, Akshay S. Desai, Pardeep S. Jhund, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan

引用次数: 0

Reply to ‘Is it possible to establish a threshold to define the inflammatory risk of acute heart failure patients?’ Letter regarding the article ‘Burst steroid therapy for acute heart failure: The CORTAHF randomized, open-label, pilot trial’ 回复 "是否有可能确定急性心力衰竭患者炎症风险的阈值？关于文章 "急性心力衰竭的突发类固醇治疗：CORTAHF随机、开放标签试点试验

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-22 DOI: 10.1002/ejhf.3491

Gad Cotter, Beth A. Davison, Yonathan Freund, Alexandre Mebazaa

引用次数: 0

Long-term exposure to fine particulate matter constituents, genetic susceptibility, and incident heart failure among 411 807 adults. 411 807 名成年人长期暴露于细颗粒物成分、遗传易感性和心力衰竭事件。

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-22 DOI: 10.1002/ejhf.3486

Feipeng Cui,Lei Zheng,Jing Zhang,Linxi Tang,Yudiyang Ma,Dankang Li,Jianing Wang,Meiqi Xing,Junqing Xie,Jian Yang,Yaohua Tian

{"title":"Long-term exposure to fine particulate matter constituents, genetic susceptibility, and incident heart failure among 411 807 adults.","authors":"Feipeng Cui,Lei Zheng,Jing Zhang,Linxi Tang,Yudiyang Ma,Dankang Li,Jianing Wang,Meiqi Xing,Junqing Xie,Jian Yang,Yaohua Tian","doi":"10.1002/ejhf.3486","DOIUrl":"https://doi.org/10.1002/ejhf.3486","url":null,"abstract":"AIMSLong-term fine particulate matter (PM2.5) exposure has been linked to incident heart failure (HF), but the impacts of its constituents remain unknown. We aimed to investigate the associations of PM2.5 constituents with incident HF, and further evaluate the modification effects of genetic susceptibility.METHODS AND RESULTSPM2.5 and its constituents, including elemental carbon (EC), organic matter (OM), ammonium (NH4 +), nitrate (NO3 -), and sulfate (SO4 2-), were estimated using the European Monitoring and Evaluation Programme model applied to the UK (EMEP4UK) driven by Weather and Research Forecast model meteorology. A polygenic risk score (PRS) was calculated to represent genetic susceptibility to HF. We employed Cox models to evaluate the associations of PM2.5 constituents with incident HF. Quantile-based g-computation model was used to identify the main contributor of PM2.5 constituents. Among 411 807 individuals in the UK Biobank, 7554 participants developed HF during a median follow-up of 12.05 years. The adjusted hazard ratios of HF for each interquartile range increase in PM2.5, EC, OM, NH4 +, NO3 -, and SO4 2- were 1.50 (1.46-1.54), 1.31 (1.27-1.34), 1.12 (1.09-1.15), 1.42 (1.41-1.44), 1.26 (1.23-1.29), and 1.25 (1.24-1.26), respectively. EC (43%) played the most important role, followed by NH4 + and SO4 2-. Moreover, synergistic additive interactions accounted for 9-16% of the HF events in individuals exposed to both PM2.5, NH4 +, NO3 -, and SO4 2- and PRS.CONCLUSIONLong-term exposure to PM2.5 constituents may elevate HF risk, and EC was the major contributor. Additive effects of PM2.5 constituents and PRS on HF risk were revealed.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"14 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A clinical classification method with outstanding advantages for quickly identifying hazardous types 一种临床分类方法，在快速识别危险类型方面具有突出优势

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-18 DOI: 10.1002/ejhf.3479

Lanxin Zhu, Jingnan Liu, Huihui Zhao

引用次数: 0

Microvascular obstruction in cardiac amyloidosis 心脏淀粉样变性中的微血管阻塞

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-18 DOI: 10.1002/ejhf.3481

Lucrezia Netti, Adam Ioannou, Ana Martinez-Naharro, Yousuf Razvi, Aldostefano Porcari, Lucia Venneri, Viviana Maestrini, Dan Knight, Ruta Virsinskaite, Muhammad U. Rauf, Tushar Kotecha, Rishi K. Patel, Ashutosh Wechelakar, Helen Lachmann, Peter Kellman, Charlotte Manisty, James Moon, Philip N. Hawkins, Julian D. Gillmore, Marianna Fontana

引用次数: 0

Reply to ‘A clinical classification method with outstanding advantages for quickly identifying hazardous types’ 对 "一种具有突出优势的临床分类方法，可快速识别危险类型 "的答复

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-18 DOI: 10.1002/ejhf.3480

Ovidiu Chioncel

引用次数: 0

What's new in heart failure? October 2024 心力衰竭有何新进展？2024 年 10 月

IF 16.9 1区医学

European Journal of Heart Failure Pub Date : 2024-10-14 DOI: 10.1002/ejhf.3492

Matthew M.Y. Lee, Pau Codina, Daniela Tomasoni, Alberto Aimo

引用次数: 0

Risk scoring in pulmonary hypertension: One size fits all? 肺动脉高压的风险评分：一刀切？

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-09 DOI: 10.1002/ejhf.3459

Irene M. Lang, Vladimir Gojic

引用次数: 0

Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial 根据射血分数评估 2 型糖尿病患者使用艾塞那肽治疗心血管疾病的效果：EXSCEL试验

IF 18.2 1区医学

European Journal of Heart Failure Pub Date : 2024-10-09 DOI: 10.1002/ejhf.3478

João Sérgio Neves, Ana Rita Leite, Robert J. Mentz, Rury R. Holman, Faiez Zannad, Javed Butler, Milton Packer, João Pedro Ferreira

引用次数: 0

Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial. 心力衰竭住院后使用托塞米和呋塞米的利尿剂剂量和疗效：TRANSFORM-HF 试验。

IF 16.9 1区医学

European Journal of Heart Failure Pub Date : 2024-10-04 DOI: 10.1002/ejhf.3458

Nina Nouhravesh, Stephen J Greene, Robert Clare, Daniel Wojdyla, Kevin J Anstrom, Eric Velazquez, Bertram Pitt, Robert J Mentz, Mitchell A Psotka

{"title":"Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial.","authors":"Nina Nouhravesh, Stephen J Greene, Robert Clare, Daniel Wojdyla, Kevin J Anstrom, Eric Velazquez, Bertram Pitt, Robert J Mentz, Mitchell A Psotka","doi":"10.1002/ejhf.3458","DOIUrl":"10.1002/ejhf.3458","url":null,"abstract":"Aims: The TRANSFORM-HF trial found no difference in clinical outcomes between torsemide versus furosemide after hospitalization for heart failure. This analysis aimed to assess the impact of diuretic dosing on the primary and secondary clinical outcomes.Methods and results: This post-hoc analysis of TRANSFORM-HF categorized patients into three groups by discharge diuretic dose: (1) ≤40 mg, (2) >40-80 mg, and (3) >80 mg of furosemide equivalents. The associations between discharge dose and 12-month clinical events, and change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), were assessed. Overall, 2379 patients were included, aged 65 years (interquartile range 56-75), 883 (37.1%) women, and 812 (34.2%) Black. Furosemide had adjusted hazard ratios (aHR) for all-cause mortality of 1.21 (95% confidence interval [CI] 0.91-1.59) for discharge dose group 2 and 1.40 (95% CI 1.04-1.88) for group 3, compared with group 1. For torsemide, aHRs were 1.74 (95% CI 1.32-2.30) for group 2 and 1.58 (95% CI 1.14-2.19) for group 3. No evidence of heterogeneity for the association between increased mortality and higher dose was found by loop diuretic type (pinteraction = 0.17). Higher doses of furosemide and torsemide were associated with increased risk of all-cause hospitalization and the composite of all-cause mortality and hospitalization, without evidence of heterogeneity by loop diuretic type (pinteraction > 0.2). Changes in KCCQ-CSS from baseline at 12 months was similar across dose groups for both drugs.Conclusion: Following hospitalization for heart failure, higher loop diuretic dosing was independently associated with worse clinical and patient-reported outcomes. The correlation between higher loop diuretic dose and outcomes was consistent, regardless of loop diuretic used.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142370402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0